<DOC>
	<DOCNO>NCT00151866</DOCNO>
	<brief_summary>The purpose study evaluate clinical efficacy transfusion platelet store platelet additive solution II compare plasma storage .</brief_summary>
	<brief_title>Efficacy Transfusions With Platelets Stored Platelet Additive Solution II Versus Plasma</brief_title>
	<detailed_description>Introduction : Utilization platelet additive solution ( PASs ) storage platelet several advantage , however randomised study test clinical efficacy scarce . A prospective , randomise study compare efficacy transfusion platelet store Platelet Additive Solution II ( PAS II ) versus plasma show CCIs transfusion platelet store PAS II significantly low ( 1 ) . Major drawback study exclusion patient clinical factor know increase platelet consumption limit number patient . A multicenter , randomise study investigate clinical efficacy platelet store PAS II versus plasma , also include patient factor increase platelet consumption , perform . Methods : After consent patient &gt; 18 year , without HLA- and/or HPA-alloantibodies , randomise receive pool platelet concentrate ( PC ) suspend either plasma PAS II , leucoreduced , store 5 day . 1- 24-hour CCI primary endpoint . Secondary endpoint transfusion interval , adverse reaction bleed complication . An inclusion-period defined maximum 8 transfusion 30 day first transfusion .</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<criteria>patient &gt; 18 year expect receive platelet transfusion inform consent HLA and/or HPA alloimmunization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Thrombopenia</keyword>
	<keyword>Platelet transfusion</keyword>
	<keyword>Increment</keyword>
	<keyword>Transfusion reaction</keyword>
	<keyword>Bleeding complication</keyword>
</DOC>